Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3

Kristy St. Rose, Jun Yan, Fangxi Xu, Jasmine Williams, Virginia Dweck, Deepak Saxena, Robert F. Schwabe, Jorge Matias Caviglia – 2 August 2022 – Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States and the world; with no Food and Drug Administration–approved pharmacological treatment available, it remains an area of unmet medical need. In nonalcoholic steatohepatitis (NASH), the most important predictor of clinical outcome is the fibrosis stage.

HCC EV ECG score: An extracellular vesicle‐based protein assay for detection of early‐stage hepatocellular carcinoma

Na Sun, Ceng Zhang, Yi‐Te Lee, Benjamin V. Tran, Jing Wang, Hyoyong Kim, Junseok Lee, Ryan Y. Zhang, Jasmine J. Wang, Junhui Hu, Zhicheng Zhang, Manaf S. Alsudaney, Kuan‐Chu Hou, Hubert Tang, Tiffany X. Zhang, Icy Y. Liang, Ziang Zhou, Mengxiang Chen, Angela Hsiao‐Jiun Yeh, Wenyuan Li, Xianghong Jasmine Zhou, Helena R. Chang, Steven‐Huy B. Han, Saeed Sadeghi, Richard S. Finn, Sammy Saab, Ronald W. Busuttil, Mazen Noureddin, Walid S. Ayoub, Alexander Kuo, Vinay Sundaram, Buraq Al‐Ghaieb, Juvelyn Palomique, Kambiz Kosari, Irene K. Kim, Tsuyoshi Todo, Nicholas N.

Association of serum metabolites and gut microbiota at hospital admission with nosocomial infection development in patients with cirrhosis

Jasmohan S. Bajaj, K. Rajender Reddy, Puneeta Tandon, Guadalupe Garcia‐Tsao, Patrick S. Kamath, Jacqueline G. O'Leary, Florence Wong, Jennifer Lai, Hugo Vargas, Paul J. Thuluvath, Ram M. Subramanian, Marcela Pena‐Rodriguez, Masoumeh Sikaroodi, Leroy R. Thacker, Patrick M. Gillevet – 29 July 2022 – Cirrhosis is complicated by a high rate of nosocomial infections (NIs), which result in poor outcomes and are challenging to predict using clinical variables alone. Our aim was to determine predictors of NI using admission serum metabolomics and gut microbiota in inpatients with cirrhosis.

Subscribe to